Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) EBITDA Margin: 2023-2025

Historic EBITDA Margin for CG Oncology (CGON) over the last 2 years, with Sep 2025 value amounting to -3,068.97%.

  • CG Oncology's EBITDA Margin rose 6273336.00% to -3,068.97% in Q3 2025 from the same period last year, while for Sep 2025 it was -8,124.63%, marking a year-over-year increase of 590637.00%. This contributed to the annual value of -10,067.25% for FY2024, which is 1711363.00% up from last year.
  • As of Q3 2025, CG Oncology's EBITDA Margin stood at -3,068.97%, which was up 96.22% from -81,161.54% recorded in Q1 2025.
  • CG Oncology's EBITDA Margin's 5-year high stood at -3,068.97% during Q3 2025, with a 5-year trough of -1,935,500.00% in Q4 2023.
  • In the last 3 years, CG Oncology's EBITDA Margin had a median value of -23,290.99% in 2024 and averaged -253,606.61%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first soared by 192,715,592bps in 2024, then slumped by 7,691,409bps in 2025.
  • Quarterly analysis of 3 years shows CG Oncology's EBITDA Margin stood at -1,935,500.00% in 2023, then surged by 192,715,592bps to -8,344.08% in 2024, then skyrocketed by 6,273,336bps to -3,068.97% in 2025.
  • Its EBITDA Margin stands at -3,068.97% for Q3 2025, versus -81,161.54% for Q1 2025 and -8,344.08% for Q4 2024.